Skip to main content
EJNMMI Research
Download PDF
  • Original research
  • Open access
  • Published:

Test-retest reproducibility of [11C]-l-deprenyl-D2 binding to MAO-B in the human brain

EJNMMI Research volume 7, Article number: 54 (2017) Cite this article

Abstract

Background

[11C]-l-deprenyl-D2 is a positron emission tomography (PET) radioligand for measurement of the monoamine oxidase B (MAO-B) activity in vivo brain. The estimation of the test-retest reproducibility is important for accurate interpretation of PET studies.

Results

We performed two [11C]-l-deprenyl-D2 scans for six healthy subjects and evaluated the test-retest variability of this radioligand. MAO-B binding was quantified by two tissue compartment model (2TCM) with three rate constants (K 1, k 2, k 3) using metabolite-corrected plasma radioactivity. The λk 3 defined as (K 1/k 2) × k 3 was also calculated. The correlation between MAO-B binding and age, and the effect of partial volume effect correction (PVEc) for the reproducibility were also estimated. %difference of k 3 was 2.6% (medial frontal cortex) to 10.3% (hippocampus), and that of λk 3 was 5.0% (thalamus) to 9.2% (cerebellum). Mean %difference of all regions were 5.3 and 7.0% in k 3 and λk 3, respectively. All regions showed below 10% variabilities except the hippocampus in k 3 (10.3%). Intraclass correlation coefficient (ICC) of k 3 was 0.78 (hippocampus) to 0.98 (medial frontal cortex), and that of λk 3 was 0.78 (hippocampus) to 0.95 (thalamus). Mean ICC were 0.94 and 0.89 in k 3 and λk 3, respectively. The highest positive correlation with age was observed in the hippocampus, as r = 0.75 in k 3 and 0.76 in λk 3. After PVEc, mean %difference were 5.6 and 7.2% in k 3 and λk 3, respectively. Mean ICC were 0.92 and 0.90 for k 3 and λk 3, respectively. These values were almost the same as those before PVEc.

Conclusions

The present results indicate that k 3 and λk 3 of [11C]-l-deprenyl-D2 are reliable parameters for test-retest reproducibility with healthy subjects both before and after PVEc. The studies with patients of larger sample size are required for further clinical applications.

Background

Monoamine oxidase (MAO) is an enzyme of deamination of monoamine and exists in two isoforms, MAO-A and MAO-B. MAO-B is considered as a major enzyme in dopamine metabolism in the human brain, and MAO-B inhibitors are used for the treatment of Parkinson’s disease to increase the dopamine level [1]. For Alzheimer’s disease (AD), several studies reported the upregulation of MAO-B expression related to the neuroinflammatory process in the glia cells [2,3,4,5,6]. So, inhibition of MAO-B is expected to have beneficial effects in AD by reducing neurodegenerative processes.

[11C]-l-deprenyl-D2 is a positron emission tomography (PET) radioligand for measurement of the MAO-B activity in the brain [7]. This radioligand was used for many PET studies to evaluate MAO-B inhibitors’ occupancy [8, 9], pathology of AD [10,11,12], amyotrophic lateral sclerosis (ALS) [13], traumatic brain injury [14], and epilepsy [15,16,17]. In addition to the clinical studies, [11C]-l-deprenyl-D2 showed good result reproducibility in a test-retest protocol [18].

Recently, we reported the brain occupancy of MAO-B using [11C]-l-deprenyl-D2 after administration of a MAO-B inhibitor, sembragiline, in controls and patients with AD [9]. Although the good reproducibility of [11C]-l-deprenyl-D2 has already been reported, confirmation in test-retest variability studies by using identical protocol settings, including radioligand production and PET machine, is helpful for accurate interpretation of occupancy. Additionally, age effect of [11C]-l-deprenyl-D2 should be estimated since an increase of MAO-B expression has been reported in elderly subjects by postmortem [19] and in vivo PET [20] studies. The partial volume effect (PVE) should be also considered in the PET studies for aged subjects or AD patients with brain atrophy [21, 22].

In this study, we focused on three issues. First, we evaluated the test-retest variability of [11C]-l-deprenyl-D2 in the healthy subjects who were scanned twice. Second, the correlation between MAO-B activity and age was estimated. Finally, the effect of partial volume effect correction (PVEc) for the reproducibility was also estimated.

Methods

Subjects

Six healthy volunteers (age range, 21–62 years; mean ± SD, 39.0 ± 17.0; four males, two females) were enrolled in the study. None had a history of present or past psychiatric, neurological, or somatic disorders, or alcohol or drug-related problems. They took no medication at the time of the study. After thorough explanation of the study, written informed consent was obtained from all participants. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden, and the Radiation Safety Committee at the Karolinska University Hospital Solna in Stockholm, Sweden.

PET procedures

[11C]-l-deprenyl-D2 was prepared by N-methylation of the desmethyl l-deprenyl-D2 precursor using [11C]methyl triflate as previously reported [9]. PET scans were carried out with the ECAT Exact HR 47 (Siemens/CTI, Knoxville, TN, USA), with an in-plane and an axial resolution of 3.6 and 4.0 mm at full width at half maximum (FWHM), respectively. A head fixation system with an individual plaster helmet was used. A 5-min transmission scan was performed using three rotating 68Ge rod sources. Dynamic PET scan was performed for 63 min (10 s × 9, 15 s × 2, 20 s × 3, 30 s × 4, 1 min × 4, 3 min × 4, 6 min × 7) after intravenous bolus injection of [11C]-l-deprenyl-D2. Injected radioactivity was 299–520 MBq (419 ± 68 MBq), which were adjusted by body weight. Specific radioactivity was 104–341 GBq/μmol (179 ± 80 GBq/μmol) at the time of injection. Injected mass was 0.24–0.77 μg (0.50 ± 0.18 μg). Two PET scans were performed for each subject in the morning and in the afternoon on the same day.

Arterial blood sampling

Arterial blood was collected continuously for 10 min using an automated blood sampling system at a speed of 5 mL/min. Arterial blood was also drawn manually 1, 2, 4, 6, 8, 10, 15, 20, 30, 45, and 60 min after the injection for measurement of radioactivity in whole blood and plasma. The parent fraction of the radioligand was determined using a reversed-phase high-performance liquid chromatography (HPLC) method at 4, 10, 20, 30, 45, and 60 min. Plasma input function was defined as radioactivity of plasma multiplied by the percentage of unchanged radioligand.

Data analysis

PET images were reconstructed using the standard filtered back projection with a 2-mm Hanning filter, a zoom factor of 2.17, and a 128 × 128 matrix, and were corrected for attenuation and scatter. T1-weighted magnetic resonance imaging (MRI) was performed using a 1.5-T Siemens MAGNETOM Avanto for definition of anatomical brain regions and PVEc. The MR image was segmented into grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) segments, using the SPM5 segmentation algorithm in MATLAB (Wellcome Trust Centre for Neuroimaging, London, UK; The MathWorks, Inc., Natick, MA, USA). Regions of interest (ROI) were defined as the cerebellum, hippocampus, lateral frontal cortex, lateral occipital cortex, lateral parietal cortex, lateral temporal cortex, medial frontal cortex, putamen, and thalamus using the Anatomical Automatic Labeling (AAL) template [23]. GM masking was applied to the AAL template. All MRIs and ROIs were co-registered to summated PET images with the mutual information algorithm using SPM5. Regional radioactivity was calculated for each frame, corrected for decay, and plotted vs. time.

MAO-B binding of [11C]-l-deprenyl-D2 was quantified by two tissue compartment model (2TCM) with three rate constants (K 1, k 2, k 3) using metabolite-corrected plasma radioactivity as the input function. k 4 was set as 0 according to the assumption of irreversible binding of [11C]-l-deprenyl-D2 [7, 18]. Blood volume was fixed as 5%. The λk 3 defined as (K 1/k 2) × k 3 was also calculated. These analyses were performed using the PMOD 3.4 software package (PMOD Group, Zurich, Switzerland).

PVEc

All PET data were corrected for PVE according to the method reported by Müller-Gärtner et al. [21]. In short, this PVEc corrects for spillover between GM and WM, and between GM and CSF using the segmented MR images. By assuming that the radioligand binding in WM is perfectly homogenous, every WM-voxel were replaced by an average value derived from an isolated proportion of WM at the centrum semiovale [22].

Statistics

The test-retest variability of MAO-B binding as k 3 and λk 3 was expressed by the absolute difference between the first and second PET scans (PET1 and PET2) relative to the mean of the two values according to the following equation [24, 25]:

$$ \%\mathrm{difference}=\left|\mathrm{PET}1-\mathrm{PET}2\right|/\left(\left(\mathrm{PET}1+\mathrm{PET}2\right)/2\right)\times 100 $$

PET1 and PET2 are the parameters (k 3 or λk 3) of first and second PET scans, respectively.

Intraclass correlation coefficient (ICC) was also calculated by:

$$ \mathrm{I}\mathrm{C}\mathrm{C}=\left(\mathrm{MSBS}-\mathrm{MSWS}\right)/\left(\mathrm{MSBS}+\mathrm{MSWS}\right) $$

MSBS is the mean square of between subject, and MSWS is the mean square of within subject.

The correlation between MAO-B binding as k 3 or λk 3 and age was estimated using the Pearson correlation coefficient.

The effect of PVEc was estimates by the %change of before and after PVEc of all parameters, K 1, k 2, k 3, and λk 3:

$$ \%\mathrm{change}=\left(\mathrm{after}\ \mathrm{PVEc}-\mathrm{before}\ \mathrm{PVEc}\right)/\mathrm{before}\ \mathrm{PVEc}\times 100 $$

In both analysis of age effect and PVEc, average values of PET1 and PET2 were used. Finally, the test-retest variability of after PVEc was estimated as same way as before PVEc.

These statistical analyses were performed using R 3.3.2 (The R Foundation, Vienna, Austria).

Results

Test-retest variability

Mean and SD values of six subjects in PET1 and PET2, mean and range of %differences, and ICC in all regions are shown in Table 1. %difference of k 3 was 2.6% (medial frontal cortex) to 10.3% (hippocampus), and that of λk 3 was 5.0% (thalamus) to 9.2% (cerebellum). Mean %difference of nine regions were 5.3% and 7.0% in k 3 and λk 3, respectively. All regions showed variability below 10%, except the hippocampus in k 3 (10.3%). ICC of k 3 was 0.78 (hippocampus) to 0.98 (medial frontal cortex), and that of λk 3 was 0.78 (hippocampus) to 0.95 (thalamus). Mean ICC of nine regions were 0.94 and 0.89 in k 3 and λk 3, respectively.

Table 1 Mean and SD values in PET1 and PET2, mean and range of %differences, and ICC in all regions of k 3 and λk 3
Full size table

Age effect

The Pearson correlation coefficient and p value between k 3 or λk 3 and age in all regions are shown in Table 2. The highest positive correlation was observed in the hippocampus (r = 0.75 in k 3 and 0.76 in λk 3; Fig. 1a, b). Regardless, both results were not statistically significant (p = 0.08 and p = 0.08, respectively).

Table 2 The Pearson correlation coefficient and p value between age and parameters in all regions of k 3 and λk 3
Full size table
Fig. 1
figure 1

The relationship between age and a k 3 or b λk 3 of six subjects

Full size image

PVEc

After PVEc, K 1 values increased as 36.9 to 62.7% according to the age (Fig. 2). %change of λk 3 was 23.5 to 37.0% and also correlated with age. Compared to K 1 and λk 3, k 2 and k 3 showed only small changes after PVEc (11.6 to 15.4% and −1.3 to 5.5%, respectively).

Fig. 2
figure 2

The relationship between age and %change of parameters (K 1, k 2, k 3, and λk 3) after PVEc of six subjects

Full size image

Mean and SD values of six subjects in PET1 and PET2, mean and range of %differences, and ICC after PVEc in all regions are shown in Table 3. Mean %difference of nine regions were 5.6 and 7.2% in k 3 and λk 3, respectively. Mean ICC of nine regions were 0.92 and 0.90 in k 3 and λk 3, respectively. These values were almost the same as those before PVEc.

Table 3 Mean and SD values in PET1 and PET2, mean and range of %differences, and ICC in all regions of k 3 and λk 3 after PVEc
Full size table

Discussion

In this study, the test-retest variability of [11C]-l-deprenyl-D2 was estimated using healthy subjects. Mean of absolute %difference in nine regions of λk 3 was 7.0%, indicating good reproducibility. The test-retest variability of λk 3 using %difference (not absolute difference) by Logan et al. was previously reported as −2.84 ± 7.07% [18]. The same calculation of our data yielded −1.1 ± 8.3%, indicating similar variability. ICC values were high in all regions, except in the hippocampus which was relatively low (0.78). It also indicated good reproducibility of [11C]-l-deprenyl-D2. Our research group recently reported the brain occupancy of MAO-B using [11C]-l-deprenyl-D2 after administration of a MAO-B inhibitor—sembragiline [9]. The study reported that oral administrations of 1–5 mg sembragiline induced near-maximal inhibition of brain MAO-B, and MAO-B occupancy was correlated with the plasma concentration of sembragiline in patients with AD. The good test-retest reproducibility of the present study using same procedure of [11C]-l-deprenyl-D2 preparation and same PET camera corroborates the findings of our previous study.

Although λk 3 is generally considered to be a more stable outcome measure than k 3 [7, 18], k 3 showed similar %difference as λk 3 (5.3 vs 7.0%) in the present study. k 3 values also showed better ICC than those of λk 3 (mean value, 0.94 vs 0.89). These findings indicate that k 3 may be independently used for further studies such as comparison between patients and healthy controls or target occupancy of MAO-B inhibitors. Obvious regional differences of reproducibility were only observed in the hippocampus. The reason of low reproducibility in the hippocampus is not clear, but one possibility is that its high k 3 value (the highest among all regions) may have induced a large variability.

In this study, two PET measurements were performed in 1 day, in the morning and afternoon. Several studies suggested that dopamine system was affected by the circadian rhythm [26,27,28]. Especially, one rodent study reported that MAO-A expression was regulated by the clock-component gene [29]. However, our result did not show the relation between the MAO-B binding and the time of PET measurements.

A moderate age effect on λk 3 values was observed in all regions. The degree of increase (6.3% per decade) was similar as the previously reported value by Fowler et al., at 7.1% per decade [20]. One postmortem study also reported increasing of MAO-B protein in the human brain according to age [19]. Our PET study confirmed both findings of postmortem and in vivo human brain studies. Among all regions, the hippocampus showed the highest correlation with age effect although it did not reach statistical significance and the reproducibility was relatively low as discussed above. Since the hippocampus is thought to be especially impacted in AD [30, 31], the present findings suggest the increase of MAO-B activity may have an important role about the pathology of AD.

PVE should be considered in PET studies when brain atrophy is observed in aged subjects or patients with disorders such as AD. Additionally, PVE is larger using a low resolution PET camera than a high resolution one. This study included elderly subjects and was conducted using relatively low resolution PET camera system compared to recent PET systems like the high resolution research tomograph (HRRT) with 1.5 mm FWHM [32]. In the present study, %change of K 1 after PVEc was correlated with age. It indicates that the brain of aged subjects was more affected by the PVE compared to younger subject due to the brain atrophy. Meanwhile, k 2 and k 3 did not show any clear change after PVEc. λk 3 was also moderately affected by PVEc and correlated with age since it is partially determined by K 1/k 2. Nevertheless, although the value itself of λk 3 was increased in aged subjects, test-retest variability of λk 3 did not change after PVEc. This indicates that PVEc can reliably keep reproducibility even in the case of elderly subjects with brain atrophy.

There are several imitations in this study. Although only six subjects were included and it is relatively small sample size, the number were similar as previous test-retest studies about [11C]-l-deprenyl-D2 by Logan et al. (n = 5) [18] and other PET radioligands (n = 6–8) [25, 33]. However, the studies about age effect included larger number generally [20, 34, 35]. So, the present result about the age effect might be preliminary. Additionally, only healthy control subjects were included in this study. It is difficult to extrapolate our findings about PVEc to AD patients because the elderly ones showed slight atrophy but not pathological. To more accurately estimate the effects of PVEc, further studies with AD patients and aged control subjects who showed strong atrophy will be needed.

Conclusions

The present results indicate that k 3 and λk 3 of [11C]-l-deprenyl-D2 are reliable parameters for test-retest reproducibility with healthy subjects both before and after PVEc. As the number of subjects was relatively small and only healthy subjects were included, the studies with patients of larger sample size are required for further clinical applications.

Abbreviations

2TCM:

Two tissue compartment model

AAL:

Anatomical Automatic Labeling

AD:

Alzheimer’s disease

ALS:

Amyotrophic lateral sclerosis

CSF:

Cerebrospinal fluid

FWHM:

Full width at half maximum

GM:

Grey matter

HRRT:

High resolution research tomograph

ICC:

Intraclass correlation coefficient

MAO:

Monoamine oxidase

MRI:

Magnetic resonance image

MSBS:

Mean square of between subject

MSWS:

Mean square of within subject

PET:

Positron emission tomography

PVE:

Partial volume effect

PVEc:

Partial volume effect correction

ROI:

Regions of interest

WM:

White matter

References

  1. Finberg JPM. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143:133–52.

    Article  CAS  PubMed  Google Scholar 

  2. Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58:60–8.

    Article  PubMed  Google Scholar 

  3. Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N, Jazin EE. Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer’s disease patients. Neurosci Lett. 2002;326:56–60.

    Article  CAS  PubMed  Google Scholar 

  4. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15–30.

    Article  CAS  PubMed  Google Scholar 

  5. Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience. 1991;45:1–12.

    Article  CAS  PubMed  Google Scholar 

  6. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 1990;80:419–25.

    Article  CAS  PubMed  Google Scholar 

  7. Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med. 1995;36:1255–62.

    CAS  PubMed  Google Scholar 

  8. Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009;85:506–12.

    Article  CAS  PubMed  Google Scholar 

  9. Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline. Eur J Nucl Med Mol Imaging. 2017;44(3):382–91.

  10. Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37–46.

    Article  CAS  PubMed  Google Scholar 

  11. Choo ILH, Carter SF, Schöll ML, Nordberg A. Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients. Eur J Nucl Med Mol Imaging. 2014;41:2120–6.

    Article  CAS  PubMed  Google Scholar 

  12. Santillo AF, Gambini JP, Lannfelt L, Långström B, Ulla-Marja L, Kilander L, et al. In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011;38:2202–8.

    Article  PubMed  Google Scholar 

  13. Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius S-M, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007;255:17–22.

    Article  CAS  PubMed  Google Scholar 

  14. Fowler JS, Volkow ND, Cilento R, Wang GJ, Felder C, Logan J. Comparison of brain glucose metabolism and monoamine oxidase B (MAO B) in traumatic brain injury. Clin Positron Imaging. 1999;2:71–9.

    Article  PubMed  Google Scholar 

  15. Bergström M, Kumlien E, Lilja A, Tyrefors N, Westerberg G, Långström B. Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl—analysis of kinetic data. Acta Neurol Scand. 1998;98:224–31.

    Article  PubMed  Google Scholar 

  16. Kumlien E, Bergström M, Lilja A, Andersson J, Szekeres V, Westerberg CE, et al. Positron emission tomography with [11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia. 1995;36:712–21.

    Article  CAS  PubMed  Google Scholar 

  17. Kumlien E, Nilsson A, Hagberg G, Långström B, Bergström M. PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy. Acta Neurol Scand. 2001;103:360–6.

    Article  CAS  PubMed  Google Scholar 

  18. Logan J, Fowler JS, Volkow ND, Wang GJ, MacGregor RR, Shea C. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol. 2000;27:43–9.

    Article  CAS  PubMed  Google Scholar 

  19. Tong J, Meyer JH, Furukawa Y, Boileau I, Chang L-J, Wilson AA, et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33:863–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–5.

    Article  CAS  PubMed  Google Scholar 

  21. Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12:571–83.

    Article  PubMed  Google Scholar 

  22. Schain M, Tóth M, Cselényi Z, Stenkrona P, Halldin C, Farde L, et al. Quantification of serotonin transporter availability with [11C]MADAM—a comparison between the ECAT HRRT and HR systems. Neuroimage. 2012;60:800–7.

    Article  CAS  PubMed  Google Scholar 

  23. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.

    Article  CAS  PubMed  Google Scholar 

  24. Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, et al. Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging. 2016;43:173–83.

    Article  CAS  PubMed  Google Scholar 

  25. Nord M, Finnema SJ, Schain M, Halldin C, Farde L. Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. Eur J Nucl Med Mol Imaging. 2014;41:301–7.

    Article  CAS  PubMed  Google Scholar 

  26. Cervenka S, Halldin C, Farde L. Age-related diurnal effect on D2 receptor binding: a preliminary PET study. Int J Neuropsychopharmacol. 2008;11:671–8.

    Article  CAS  PubMed  Google Scholar 

  27. Minton GO, Young AH, McQuade R, Fairchild G, Ingram CD, Gartside SE. Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder. Neuropsychopharmacology. 2009;34:2265–74.

    Article  CAS  PubMed  Google Scholar 

  28. Huang J, Zhong Z, Wang M, Chen X, Tan Y, Zhang S, et al. Circadian modulation of dopamine levels and dopaminergic neuron development contributes to attention deficiency and hyperactive behavior. J Neurosci. 2015;35:2572–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hampp G, Ripperger JA, Houben T, Schmutz I, Blex C, Perreau-Lenz S, et al. Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood. Curr Biol. 2008;18:678–83.

    Article  CAS  PubMed  Google Scholar 

  30. Braskie MN, Thompson PM. A focus on structural brain imaging in the Alzheimer’s disease neuroimaging initiative. Biol Psychiatry. 2014;75:527–33.

    Article  PubMed  Google Scholar 

  31. de Flores R, La Joie R, Chételat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease. Neuroscience. 2015;309:29–50.

    Article  PubMed  Google Scholar 

  32. Varrone A, Sjöholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639–50.

    Article  PubMed  Google Scholar 

  33. Jučaite A, Cselényi Z, Arvidsson A, Ahlberg G, Julin P, Varnäs K, et al. Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain—a PET study in control subjects. EJNMMI Res. 2012;2:15.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, et al. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: a PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. Neuroimage. 2017;152:330–9.

    Article  CAS  PubMed  Google Scholar 

  35. Matuskey D, Worhunksy P, Correa E, Pittman B, Gallezot J-D, Nabulsi N, et al. Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers. Neuroimage. 2016;130:241–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all members of the Karolinska Insitutet PET Centre for assistance with the PET experiments. RSM was recipient of a post doc fellowship (CNPq-23364/2014-7).

Funding

This work was partially supported by GE Healthcare Ltd., UK.

Authors’ contributions

PS, AT, and CH designed the study and wrote the protocol. PS and SN conducted the PET experiment. RA, PS, AT, and RSM analyzed the data. RA wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable

Ethics approval and consent to participate

The study was approved by the Regional Ethical Review Board in Stockholm, Sweden, and the Radiation Safety Committee at the Karolinska University Hospital in Solna in Stockholm, Sweden. After thorough explanation of the study, written informed consent was obtained from all participants.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Authors and Affiliations

  1. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden

    Ryosuke Arakawa, Per Stenkrona, Akihiro Takano, Sangram Nag, Rafael S. Maior & Christer Halldin

  2. Primate Center and Laboratory of Neurosciences and Behavior, Department of Physiological Sciences, Institute of Biology, University of Brasilia, Brasilia, Brazil

    Rafael S. Maior

Authors
  1. Ryosuke Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per Stenkrona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akihiro Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sangram Nag
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafael S. Maior
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christer Halldin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryosuke Arakawa.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arakawa, R., Stenkrona, P., Takano, A. et al. Test-retest reproducibility of [11C]-l-deprenyl-D2 binding to MAO-B in the human brain. EJNMMI Res 7, 54 (2017). https://doi.org/10.1186/s13550-017-0301-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13550-017-0301-4

Keywords